← Back to Search

Biomarker Validation Tests for Mesothelioma

N/A

Recruiting

Led By Raphael Bueno, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants must be 18 years of age or older.

All adult patients with a diagnosis of malignant pleural mesothelioma undergoing diagnostic pleural biopsy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 years

Awards & highlights

Study Summary

This trial is testing a new way to figure out how advanced someone's mesothelioma is and what their outlook is.

Who is the study for?

This trial is for adults diagnosed with malignant pleural mesothelioma who are undergoing various procedures like VATS resections, diagnostic pleural biopsy, or pleuroscopy. It's not suitable for patients deemed unfit for surgery, treatment, or diagnosis.Check my eligibility

What is being tested?

The study is evaluating new tests called MPT Test and CLDN15/VIM Test to better determine the stage and prognosis of malignant pleural mesothelioma in individuals undergoing specific medical procedures.See study design

What are the potential side effects?

Since this trial involves diagnostic tests rather than treatments, there may be minimal side effects related to the procedure itself such as discomfort at the biopsy site or a low risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am an adult diagnosed with mesothelioma and will have a biopsy.

Select...

I have been diagnosed with mesothelioma and am undergoing a specific type of surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pre-treatment Prognostic Algorithm Validation

Secondary outcome measures

Evaluation of Molecular Tests Base on RNA Expression

Trial Design

1Treatment groups

Experimental Treatment

Group I: MRiSExperimental Treatment2 Interventions

The specimens to be collected will include at least five pleural biopsy samples MPT test and the CLDN15/VIM test will be performed

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,925,641 Total Patients Enrolled

93 Trials studying Mesothelioma

8,414 Patients Enrolled for Mesothelioma

Dana-Farber Cancer InstituteLead Sponsor

1,079 Previous Clinical Trials

340,746 Total Patients Enrolled

9 Trials studying Mesothelioma

781 Patients Enrolled for Mesothelioma

Raphael Bueno, MDPrincipal Investigator - Brigham and Women's Hospital

Brigham & Women's Faulkner Hospital, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Milford Regional Medical Center

Harvard Medical Sch (Medical School)

Boston Medical Center (Residency)

4 Previous Clinical Trials

1,401 Total Patients Enrolled

2 Trials studying Mesothelioma

141 Patients Enrolled for Mesothelioma

Media Library

MPT Test Clinical Trial Eligibility Overview. Trial Name: NCT03683680 — N/A

Mesothelioma Research Study Groups: MRiS

Mesothelioma Clinical Trial 2023: MPT Test Highlights & Side Effects. Trial Name: NCT03683680 — N/A

MPT Test 2023 Treatment Timeline for Medical Study. Trial Name: NCT03683680 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is involvement in this trial open to the public at this time?

"Affirmative. Clinicaltrials.gov's records indicate that this trial, which was initially uploaded on October 31 2018, is still recruiting patients from one medical site and requires a total of 240 enrollees."

Answered by AI

What is the current capacity of this clinical research endeavor?

"Affirmative, the information available on clinicaltrials.gov implies that this investigation is currently accepting participants. This research was originally posted on October 31st 2018 and recently updated on March 21st 2022. 240 individuals need to be recruited at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Raphael Bueno, MD 2018. "Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03683680.

All > Mesothelioma